Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2009 - 2026)

Vertex Pharmaceuticals has reported Change in Accured Expenses for 18 years, with the latest figure at $70.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 46.57% year-over-year to $70.5 million; the trailing twelve-month figure through Mar 2026 stood at -$94.5 million (down 241.26% YoY), and the FY2025 full-year result was -$116.9 million, down 154.91% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $70.5 million, up from -$664.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $668.3 million in Q3 2023, with the low at -$664.5 million in Q4 2025.
• Average Change in Accured Expenses over 5 years is $67.0 million, with a median of $61.6 million recorded in 2022.
• Year-over-year, Change in Accured Expenses surged 994.11% in 2022 and slumped 1096.83% in 2024.
• Tracing VRTX's Change in Accured Expenses over 5 years: stood at -$437.8 million in 2022, then advanced by 18.52% to -$356.7 million in 2023, then increased by 10.26% to -$320.1 million in 2024, then sank by 107.59% to -$664.5 million in 2025, then soared by 110.61% to $70.5 million in 2026.
• The last three Change in Accured Expenses figures came in at $70.5 million (Q1 2026), -$664.5 million (Q4 2025), and $588.8 million (Q3 2025), per Business Quant data.

Peer Comparison